412 related articles for article (PubMed ID: 7677772)
21. Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro.
Tertov VV; Sobenin IA; Kaplun VV; Orekhov AN
Free Radic Res; 1998 Aug; 29(2):165-73. PubMed ID: 9790519
[TBL] [Abstract][Full Text] [Related]
22. [Oxidized LDL in patients with coronary heart disease and normal subjects].
Hasegawa A; Toshima S; Nakano A; Nagai R
Nihon Rinsho; 1999 Dec; 57(12):2754-8. PubMed ID: 10638208
[TBL] [Abstract][Full Text] [Related]
23. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].
Yoshida H
Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275
[TBL] [Abstract][Full Text] [Related]
24. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
25. Immunoregulatory plasma low density lipoprotein: the biologic activity and receptor-binding specificity is independent of neutral lipids.
Curtiss LK; Edgington TS
J Immunol; 1981 Mar; 126(3):1008-12. PubMed ID: 7462623
[TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein composition and oxidability in atherosclerotic cardiovascular disease.
Schreier LE; Sanguinetti S; Mosso H; Lopez GI; Siri L; Wikinski RL
Clin Biochem; 1996 Oct; 29(5):479-87. PubMed ID: 8884071
[TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study.
Koskinen J; Magnussen CG; Würtz P; Soininen P; Kangas AJ; Viikari JS; Kähönen M; Loo BM; Jula A; Ahotupa M; Lehtimäki T; Ala-Korpela M; Juonala M; Raitakari OT
Eur J Prev Cardiol; 2012 Dec; 19(6):1296-303. PubMed ID: 21960651
[TBL] [Abstract][Full Text] [Related]
28. Mapping oxidations of apolipoprotein B-100 in human low-density lipoprotein by liquid chromatography-tandem mass spectrometry.
Chakraborty S; Cai Y; Tarr MA
Anal Biochem; 2010 Sep; 404(2):109-17. PubMed ID: 20470747
[TBL] [Abstract][Full Text] [Related]
29. Low density lipoprotein for oxidation and metabolic studies. Isolation from small volumes of plasma using a tabletop ultracentrifuge.
Himber J; Bühler E; Moll D; Moser UK
Int J Vitam Nutr Res; 1995; 65(2):137-42. PubMed ID: 7591534
[TBL] [Abstract][Full Text] [Related]
30. Increased oxidizability of low-density lipoproteins in hypothyroidism.
Diekman T; Demacker PN; Kastelein JJ; Stalenhoef AF; Wiersinga WM
J Clin Endocrinol Metab; 1998 May; 83(5):1752-5. PubMed ID: 9589687
[TBL] [Abstract][Full Text] [Related]
31. Cu(2+)-induced lipid oxidation in plasma: questionable relation between cholesterol oxidation and LDL modification.
Tallineau C; Pontcharraud R; Guettier A; Piriou A
Biochem Int; 1992 Sep; 27(6):983-90. PubMed ID: 1445380
[TBL] [Abstract][Full Text] [Related]
32. In vivo oxidized low density lipoprotein: degree of lipoprotein oxidation does not correlate with its atherogenic properties.
Tertov VV; Kaplun VV; Orekhov AN
Mol Cell Biochem; 1998 Jun; 183(1-2):141-6. PubMed ID: 9655188
[TBL] [Abstract][Full Text] [Related]
33. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis.
Viigimaa M; Abina J; Zemtsovskaya G; Tikhaze A; Konovalova G; Kumskova E; Lankin V
Blood Press; 2010 Jun; 19(3):164-8. PubMed ID: 20429692
[TBL] [Abstract][Full Text] [Related]
34. Presence of a modified low density lipoprotein in humans.
Avogaro P; Bon GB; Cazzolato G
Arteriosclerosis; 1988; 8(1):79-87. PubMed ID: 3341993
[TBL] [Abstract][Full Text] [Related]
35. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia.
Napoli C; Postiglione A; Triggiani M; Corso G; Palumbo G; Carbone V; Ruocco A; Ambrosio G; Montefusco S; Malorni A; Condorelli M; Chiariello M
Atherosclerosis; 1995 Dec; 118(2):259-73. PubMed ID: 8770320
[TBL] [Abstract][Full Text] [Related]
36. [Lipid peroxidation--the factor promoting cholesterol accumulation in cells in atherogenesis].
Panasenko OM; Vol'nova TV; Azizova OA; Vladimirov IuA
Biull Eksp Biol Med; 1988 Sep; 106(9):277-80. PubMed ID: 3167175
[TBL] [Abstract][Full Text] [Related]
37. Lipid composition of circulating multiple-modified low density lipoprotein.
Zakiev ER; Sukhorukov VN; Melnichenko AA; Sobenin IA; Ivanova EA; Orekhov AN
Lipids Health Dis; 2016 Aug; 15(1):134. PubMed ID: 27558696
[TBL] [Abstract][Full Text] [Related]
38. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
Aviram M; Rosenblat M; Billecke S; Erogul J; Sorenson R; Bisgaier CL; Newton RS; La Du B
Free Radic Biol Med; 1999 Apr; 26(7-8):892-904. PubMed ID: 10232833
[TBL] [Abstract][Full Text] [Related]
39. [Cholesterol, phospholipid and apoB composition of LDL: comparison of precipitation and ultracentrifugation methods].
Mainard F; Madec Y
Ann Biol Clin (Paris); 1986; 44(6):618-23. PubMed ID: 3826778
[TBL] [Abstract][Full Text] [Related]
40. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation.
Steinbrecher UP; Lougheed M; Kwan WC; Dirks M
J Biol Chem; 1989 Sep; 264(26):15216-23. PubMed ID: 2768257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
